# Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain

> **NCT03221907** · PHASE3 · COMPLETED · sponsor: **Daewon Pharmaceutical Co., Ltd.** · enrollment: 352 (actual)

## Conditions studied

- Pain of Mononeuropathy

## Interventions

- **DRUG:** GLA5PR GLARS-NF1
- **DRUG:** GLA5PR GLARS-NF1 placebo
- **DRUG:** Pregabalin
- **DRUG:** Pregabalin placebo

## Key facts

- **NCT ID:** NCT03221907
- **Lead sponsor:** Daewon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-11
- **Primary completion:** 2019-01-08
- **Final completion:** 2019-01-08
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03221907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03221907, "Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03221907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*